

VIA HAND DELIVERY APRIL 20, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ebner et al.

Attorney Docket No.: PF399

Application Serial No.: 09/115,832

Art Unit: 1647

Filed: July 15, 1998

Examiner: Draper, G.

Title: Polynucleotides Encoding Interleukin-20 (as amended)

RECEIVED
APR 25 2001
TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97**

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys and/or Agents for Applicants hereby direct the Examiner's attention to references AP-AR listed on the attached Form PTO/SB/08. A copy of each reference is enclosed.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.


Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants believe that this Information Disclosure Statement is being filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application. Pursuant to 37 C.F.R. § 1.97(c), the Patent and Trademark Office will consider this Information Disclosure Statement if it is accompanied by either a statement as specified in 37 C.F.R. § 1.97(e) or the fee as specified in 37 C.F.R. § 1.17(p).

Accordingly, the Patent Office is hereby authorized to charge our Deposit Account No. 08-3425 in the amount of \$180.00 as payment of the fee required under 37 CFR § 1.17(p). The Patent Office is also authorized to charge any additional required fee or credit any overpayment in connection with this submission to our Deposit Account No. 08-3425.

Respectfully submitted,

Dated: April 20, 2001



Mark J. Hyman (Reg. No. 46,789)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (240) 314-1224

Enclosures